Top

Published in:

01-12-2014 | Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Extracellular Matrix Components in the Pathogenesis of Type 1 Diabetes

Authors: Marika Bogdani, Eva Korpos, Charmaine J. Simeonovic, Christopher R. Parish, Lydia Sorokin, Thomas N. Wight

Published in: Current Diabetes Reports | Issue 12/2014

Abstract

Type 1 diabetes (T1D) results from progressive immune cell-mediated destruction of pancreatic β cells. As immune cells migrate into the islets, they pass through the extracellular matrix (ECM). This ECM is composed of different macromolecules localized to different compartments within and surrounding islets; however, the involvement of this ECM in the development of human T1D is not well understood. Here, we summarize our recent findings from human and mouse studies illustrating how specific components of the islet ECM that constitute basement membranes and interstitial matrix of the islets, and surprisingly, the intracellular composition of islet β cells themselves, are significantly altered during the pathogenesis of T1D. Our focus is on the ECM molecules laminins, collagens, heparan sulfate/heparan sulfate proteoglycans, and hyaluronan, as well as on the enzymes that degrade these ECM components. We propose that islet and lymphoid tissue ECM composition and organization are critical to promoting immune cell activation, islet invasion, and destruction of islet β cells in T1D.

1.••

Hynes RO, Yamada KM. Extracellular matrix biology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2012. Excellent up-to-date coverage of different ECM components.

2.••

Karamanos N. Extracellular matrix: pathobiology and signaling. Berlin/Boston: Walter de Gruyter; 2012. Outstanding collection of chapters covering information on how different components of ECM impact cellular signaling and cell phenotype.

Mecham RP, editor. The extracellular matrix: an overview. Biology of the extracellular matrix. Berlin: Springer-Verlag; 2011.

Hay ED. Cell biology of extracellular matrix. New York: Plenum Press; 1991.CrossRef

Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol. 2010;10:712–23. doi:10.1038/nri2852.PubMedCrossRef

Pugliese A, Yang M, Kusmarteva I, Heiple T, Vendrame F, Wasserfall C, et al. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes. 2014;15:1–9. doi:10.1111/pedi.12097.PubMedCrossRef

Jiang FX, Harrison LC. Extracellular signals and pancreatic beta-cell development: a brief review. Mol Med. 2002;8:763–70.PubMedCentralPubMed

8.••

Reinert RB, Cai Q, Hong JY, Plank JL, Aamodt K, Prasad N, et al. Vascular endothelial growth factor coordinates islet innervation via vascular scaffolding. Development. 2014;141:1480–91. doi:10.1242/dev.098657. This study shows the interconnection between the vascular and neuronal system in pancreatic islet development.PubMedCrossRef

9.••

Nikolova G, Jabs N, Konstantinova I, Domogatskaya A, Tryggvason K, Sorokin L, et al. The vascular basement membrane: a niche for insulin gene expression and beta cell proliferation. Dev Cell. 2006;10:397–405. doi:10.1016/j.devcel.2006.01.015. This study shows how laminins can impact on islet development and insulin production, an area with enormous potential for improved islet transfer.PubMedCrossRef

10.

Virtanen I, Banerjee M, Palgi J, Korsgren O, Lukinius A, Thornell LE, et al. Blood vessels of human islets of Langerhans are surrounded by a double basement membrane. Diabetologia. 2008;51:1181–91. doi:10.1007/s00125-008-0997-9.PubMedCrossRef

11.

Otonkoski T, Banerjee M, Korsgren O, Thornell LE, Virtanen I. Unique basement membrane structure of human pancreatic islets: implications for beta-cell growth and differentiation. Diabetes Obes Metab. 2008;10 Suppl 4:119–27. doi:10.1111/j.1463-1326.2008.00955.x.PubMedCrossRef

12.

Pavin EJ, Pinto GA, Zollner RL, Vassallo J. Immunohistochemical study of the pancreatic basement membrane in non obese diabetic mice (NOD) with spontaneous autoimmune insulitis. J Submicrosc Cytol Pathol. 2003;35:25–7.PubMed

13.

Irving-Rodgers HF, Ziolkowski AF, Parish CR, Sado Y, Ninomiya Y, Simeonovic CJ, et al. Molecular composition of the peri-islet basement membrane in NOD mice: a barrier against destructive insulitis. Diabetologia. 2008;51:1680–8. doi:10.1007/s00125-008-1085-x.PubMedCentralPubMedCrossRef

14.••

Ziolkowski AF, Popp SK, Freeman C, Parish CR, Simeonovic CJ. Heparan sulfate and heparanase play key roles in mouse beta cell survival and autoimmune diabetes. J Clin Invest. 2012;122:132–41. doi:10.1172/JCI46177. Hallmark study identifies heparan sulfate (HS) to be critical for islet beta cell survival and HS-degrading heparanase as a novel mechanism of beta cell death in T1D.PubMedCentralPubMedCrossRef

15.••

Korpos E, Kadri N, Kappelhoff R, Wegner J, Overall CM, Weber E, et al. The peri-islet basement membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and human. Diabetes. 2013;62:531–42. doi:10.2337/db12-0432. This work shows that the peri-islet basement membrane is a barrier in front of pancreatic islet infiltrating leukocyte not only in NOD mice but also in human type 1 diabetic pancreases.PubMedCentralPubMedCrossRef

16.

Tanzer ML. Current concepts of extracellular matrix. J Orthop Sci. 2006;11:326–31. doi:10.1007/s00776-006-1012-2.PubMedCentralPubMedCrossRef

17.••

Hynes RO. The extracellular matrix: not just pretty fibrils. Science. 2009;326:1216–9. doi:10.1126/science.1176009. An excellent overview of what the ECM is and how it can impact cellular behavior.PubMedCentralPubMedCrossRef

18.

Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123:4195–200. doi:10.1242/jcs.023820.PubMedCentralPubMedCrossRef

19.

Robert L, Robert AM, Renard G. Biological effects of hyaluronan in connective tissues, eye, skin, venous wall. Role in aging Pathol Biol (Paris). 2010;58:187–98. doi:10.1016/j.patbio.2009.09.010.CrossRef

20.••

Bogdani M, Johnson PY, Potter-Perigo S, Nagy N, Day AJ, Bollyky PL, et al. Hyaluronan and hyaluronan binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulitis. Diabetes. 2014;63:2727–43. doi:10.2337/db13-1658. A thorough investigation of the involvement of hyaluronan and associated molecules in the pathogenesis of T1D.

21.

Behrens DT, Villone D, Koch M, Brunner G, Sorokin L, Robenek H, et al. The epidermal basement membrane is a composite of separate laminin- or collagen IV-containing networks connected by aggregated perlecan, but not by nidogens. J Biol Chem. 2012;287:18700–9. doi:10.1074/jbc.M111.336073.PubMedCentralPubMedCrossRef

22.

Fox JW, Mayer U, Nischt R, Aumailley M, Reinhardt D, Wiedemann H, et al. Recombinant nidogen consists of three globular domains and mediates binding of laminin to collagen type IV. EMBO J. 1991;10:3137–46.PubMedCentralPubMed

23.

Mayer U, Kohfeldt E, Timpl R. Structural and genetic analysis of laminin-nidogen interaction. Ann NY Acad Sci. 1998;857:130–42.PubMedCrossRef

24.

Mayer U, Mann K, Timpl R, Murphy G. Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling. Eur J Biochem. 1993;217:877–84.PubMedCrossRef

25.

Aumailley M, Battaglia C, Mayer U, Reinhardt D, Nischt R, Timpl R, et al. Nidogen mediates the formation of ternary complexes of basement membrane components. Kidney Int. 1993;43:7–12.PubMedCrossRef

26.

Poschl E, Schlotzer-Schrehardt U, Brachvogel B, Saito K, Ninomiya Y, Mayer U. Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. Development. 2004;131:1619–28. doi:10.1242/dev.01037.PubMedCrossRef

27.

Durbeej M. Laminins Cell Tissue Res. 2010;339:259–68. doi:10.1007/s00441-009-0838-2.CrossRef

28.

Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol. 2006;6:633–43.PubMedCrossRef

29.

Jiang FX, Naselli G, Harrison LC. Distinct distribution of laminin and its integrin receptors in the pancreas. J Histochem Cytochem. 2002;50:1625–32.PubMedCrossRef

30.

Banerjee M, Virtanen I, Palgi J, Korsgren O, Otonkoski T. Proliferation and plasticity of human beta cells on physiologically occurring laminin isoforms. Mol Cell Endocrinol. 2012;355:78–86. doi:10.1016/j.mce.2012.01.020.PubMedCrossRef

31.

Van Deijnen JH, Van Suylichem PT, Wolters GH, Van Schilfgaarde R. Distribution of collagens type I, type III and type V in the pancreas of rat, dog, pig and man. Cell Tissue Res. 1994;277:115–21.PubMedCrossRef

32.

Burns AR, Smith CW, Walker DC. Unique structural features that influence neutrophil emigration into the lung. Physiol Rev. 2003;83:309–36. doi:10.1152/physrev.00023.2002.PubMed

33.

Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7:678–89. doi:10.1038/nri2156.PubMedCrossRef

34.

Brunicardi FC, Stagner J, Bonner-Weir S, Wayland H, Kleinman R, Livingston E, et al. Microcirculation of the islets of Langerhans. Long Beach Veterans Administration Regional Medical Education Center Symposium. Diabetes. 1996;45:385–92.PubMedCrossRef

35.

Sixt M, Engelhardt B, Pausch F, Hallmann R, Wendler O, Sorokin LM. Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood–brain barrier in experimental autoimmune encephalomyelitis. J Cell Biol. 2001;153:933–46.PubMedCentralPubMedCrossRef

36.

Wang S, Voisin MB, Larbi KY, Dangerfield J, Scheiermann C, Tran M, et al. Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. J Exp Med. 2006;203:1519–32.PubMedCentralPubMedCrossRef

37.

Wu C, Ivars F, Anderson P, Hallmann R, Vestweber D, Nilsson P, et al. Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat Med. 2009;15:519–27. doi:10.1038/nm.1957.PubMedCrossRef

38.

Kenne E, Soehnlein O, Genove G, Rotzius P, Eriksson EE, Lindbom L. Immune cell recruitment to inflammatory loci is impaired in mice deficient in basement membrane protein laminin alpha4. J Leukoc Biol. 2010;88:523–8. doi:10.1189/jlb.0110043.PubMed

39.

Kappelhoff R, Overall C. The CLIP-CHIP oligonucleotide microarray: dedicated array for analysis of all protease, nonproteolytic homolog, and inhibitor gene transcripts in human and mouse. Curr Protoc Protein Sci 2007. p. Unit 21 19.

40.

Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24:241–55. doi:10.1101/gad.1874010.PubMedCentralPubMedCrossRef

41.

Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, et al. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem. 2006;281:6020–9. doi:10.1074/jbc.M509134200.PubMedCrossRef

42.

Abdul-Hussien H, Soekhoe RG, Weber E, von der Thusen JH, Kleemann R, Mulder A, et al. Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol. 2007;170:809–17. doi:10.2353/ajpath.2007.060522.PubMedCentralPubMedCrossRef

43.

Chang SH, Kanasaki K, Gocheva V, Blum G, Harper J, Moses MA, et al. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009;69:4537–44. doi:10.1158/0008-5472.PubMedCentralPubMedCrossRef

44.

Morrison CJ, Butler GS, Rodriguez D, Overall CM. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol. 2009;21:645–53. doi:10.1016/j.ceb.2009.06.006.PubMedCrossRef

45.••

Dufour A, Overall CM. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci. 2013;34:233–42. doi:10.1016/j.tips.2013.02.004. This review summarizes the novel substrates of matrix metalloproteinases in inflammation and cancer.PubMedCrossRef

46.

Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL, Kraneveld AD, Galin FS, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med. 2006;12:317–23. doi:10.1038/nm1361.PubMedCrossRef

47.

Ricard-Blum S, Salza R. Matricryptins and matrikines: biologically active fragments of the extracellular matrix. Exp Dermatol. 2014. doi:10.1111/exd.12435.PubMed

48.

Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729–77. doi:10.1146/annurev.biochem.68.1.729.

49.

Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 2002;71:435–71. doi:10.1146/annurev.biochem.71.110601.135458.PubMedCrossRef

50.

Lindahl U, Kjellen L. Pathophysiology of heparan sulphate: many diseases, few drugs. J Intern Med. 2013;273:555–71. doi:10.1111/joim.12061.PubMedCrossRef

51.

Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011;3. doi:10.1101/cshperspect.a004952.

52.

Kreuger J, Kjellen L. Heparan sulfate biosynthesis: regulation and variability. J Histochem Cytochem. 2012;60:898–907. doi:10.1369/0022155412464972.PubMedCentralPubMedCrossRef

53.

Casu B, Naggi A, Torri G. Heparin-derived heparan sulfate mimics that modulate inflammation and cancer. Matrix Biol 2010;29:442–52. doi:10.1016/j.matbio.2010.04.003.

54.

Hohenester E, Yurchenco PD. Laminins in basement membrane assembly. Cell Adh Migr. 2013;7:56–63. doi:10.4161/cam.21831.PubMedCentralPubMedCrossRef

55.

Dilts SM, Lafferty KJ. Autoimmune diabetes: the involvement of benign and malignant autoimmunity. J Autoimmun. 1999;12:229–32. doi:10.1006/jaut.1999.0284.PubMedCrossRef

56.

Solomon M, Sarvetnick N. The pathogenesis of diabetes in the NOD mouse. Adv Immunol. 2004;84:239–64. doi:10.1016/S0065-2776(04)84007-0.PubMedCrossRef

57.

Tsiapali E, Whaley S, Kalbfleisch J, Ensley HE, Browder IW, Williams DL. Glucans exhibit weak antioxidant activity, but stimulate macrophage free radical activity. Free Radic Biol Med. 2001;30:393–402. doi:10.1016/S0891-5849(00)00485-8.

58.

Takahashi I, Noguchi N, Nata K, Yamada S, Kaneiwa T, Mizumoto S, et al. Important role of heparan sulfate in postnatal islet growth and insulin secretion. Biochem Biophys Res Commun. 2009;383:113–8. doi:10.1016/j.bbrc.2009.03.140.PubMedCrossRef

59.

Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001;108:341–7. doi:10.1172/JCI13662.PubMedCentralPubMedCrossRef

60.

Couzin-Frankel J. Clinical studies. Trying to reset the clock on type 1 diabetes. Science. 2011;333:819–21. doi:10.1126/science.333.6044.819.

61.

DeWeerdt S. Immunomodulators: cell savers. Nature. 2012;485:S4–5.PubMedCrossRef

62.

Weissmann B, Meyer K. The structure of hyalobiuronic acid and of hyaluronic acid from umbilical cord. J Am Chem Soc. 1954;76:1753–7.CrossRef

63.

Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: an overview. Immunol Cell Biol. 1996;74:A1–7. doi:10.1038/icb.1996.32.PubMedCrossRef

64.

Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528–39.PubMedCrossRef

65.

Volpi N, Schiller J, Stern R, Soltes L. Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem. 2009;16:1718–45.PubMedCrossRef

66.

Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem. 2002;277:4585–8.PubMedCrossRef

67.

Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev. 2011;91:221–64. doi:10.1152/physrev.00052.2009.PubMedCentralPubMedCrossRef

68.••

Csoka AB, Stern R. Hypotheses on the evolution of hyaluronan: a highly ironic acid. Glycobiology. 2013;23:398–411. doi:10.1093/glycob/cws218. Outstanding review of functional aspects of hyaluronan biology—thought provoking.PubMedCentralPubMedCrossRef

69.

Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature. 2013;499:346–9. doi:10.1038/nature12234.PubMedCentralPubMedCrossRef

70.

Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol. 2006;85:699–715.PubMedCrossRef

71.

Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997;242:27–33.PubMedCrossRef

72.

Day AJ, de la Motte CA. Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol. 2005;26:637–43.PubMedCrossRef

73.••

Bollyky PL, Bogdani M, Bollyky JB, Hull RL, Wight TN. The role of hyaluronan and the extracellular matrix in islet inflammation and immune regulation. Curr Diab Rep. 2012;12:471–80. doi:10.1007/s11892-012-0297-0. An excellent review of how hyaluronan regulates innate and adaptive immunity.PubMedCentralPubMedCrossRef

74.

de la Motte CA. Hyaluronan in intestinal homeostasis and inflammation: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011;301:G945–9. doi:10.1152/ajpgi.00063.2011.PubMedCentralPubMedCrossRef

75.

Lesley J, Gal I, Mahoney DJ, Cordell MR, Rugg MS, Hyman R, et al. TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem. 2004;279:25745–54.PubMedCrossRef

76.

Potter-Perigo S, Johnson PY, Evanko SP, Chan CK, Braun KR, Wilkinson TS, et al. Polyinosine-polycytidylic acid stimulates versican accumulation in the extracellular matrix promoting monocyte adhesion. Am J Respir Cell Mol Biol. 2010;43:109–20. doi:10.1165/rcmb.2009-0081OC.PubMedCentralPubMedCrossRef

77.••

Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT, Wight TN. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol. 2012;31:90–100. doi:10.1016/j.matbio.2011.10.004. A nice demonstration of how these components affect T-cell phenotype.PubMedCentralPubMedCrossRef

78.••

Baranova NS, Foulcer SJ, Briggs DC, Tilakaratna V, Enghild JJ, Milner CM, et al. Inter-α-inhibitor impairs TSG-6 induced hyaluronan cross-linking. J Biol Chem. 2013;288:29642–53. doi:10.1074/jbc.M113.477422. Insightful study demonstrating key molecules in the generation of high molecular complexes of hyaluronan.PubMedCentralPubMedCrossRef

79.

Wang A, de la Motte C, Lauer M, Hascall V. Hyaluronan matrices in pathobiological processes. FEBS J. 2011;278:1412–8. doi:10.1111/j.1742-4658.2011.08069.x.PubMedCrossRef

80.

Baranova NS, Nileback E, Haller FM, Briggs DC, Svedhem S, Day AJ, et al. The inflammation-associated protein TSG-6 cross-links hyaluronan via hyaluronan-induced TSG-6 oligomers. J Biol Chem. 2011;286:25675–86. doi:10.1074/jbc.M111.247395.PubMedCentralPubMedCrossRef

81.

Stern R, Jedrzejas MJ. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev. 2006;106:818–39. doi:10.1021/cr050247k.PubMedCentralPubMedCrossRef

82.

Teder P, Vandivier RW, Jiang D, Liang J, Cohn L, Pure E, et al. Resolution of lung inflammation by CD44. Science. 2002;296:155–8.PubMedCrossRef

83.

Powell JD, Horton MR. Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal. Immunol Res. 2005;31:207–18.PubMedCrossRef

84.

Atkinson MA, Gianani R. The pancreas in human type 1 diabetes: providing new answers to age-old questions. Curr Opin Endocrinol Diabetes Obes. 2009;16:279–85. doi:10.1097/MED.0b013e32832e06ba.PubMedCrossRef

85.

Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5:219–26. doi:10.1038/nrendo.2009.21.PubMedCrossRef

86.

Galandrini R, Galluzzo E, Albi N, Grossi CE, Velardi A. Hyaluronate is costimulatory for human T cell effector functions and binds to CD44 on activated T cells. J Immunol. 1994;153:21–31.PubMed

87.

Mummert ME, Mohamadzadeh M, Mummert DI, Mizumoto N, Takashima A. Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking. J Exp Med. 2000;192:769–79.PubMedCentralPubMedCrossRef

88.

Mummert ME, Mummert D, Edelbaum D, Hui F, Matsue H, Takashima A. Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation. J Immunol. 2002;169:4322–31.PubMedCrossRef

89.

Mummert ME. Immunologic roles of hyaluronan. Immunol Res. 2005;31:189–206.PubMedCrossRef

90.

Bollyky P, Evanko S, Wu R, Potter-Perigo S, Long S, Kinsella B, et al. TH1 cytokines promote hyaluronan production by antigen presenting cells and accumulation at the immune synapse. Cell Mol Immunol. 2010;7:211–20. doi:10.1038/cmi.2010.9.PubMedCentralPubMedCrossRef

91.

Weiss L, Slavin S, Reich S, Cohen P, Shuster S, Stern R, et al. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc Natl Acad Sci U S A. 2000;97:285–90.PubMedCentralPubMedCrossRef

92.••

Kota DJ, Wiggins LL, Yoon N, Lee RH. TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity. Diabetes. 2013;62:2048–58. doi:10.2337/db12-0931. Interesting study implicating a hyaluronan binding protein as a possible therapeutic target to treat T1D.PubMedCentralPubMedCrossRef

93.

Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009;155:173–81. doi:10.1111/j.1365-2249.2008.03860.x.PubMedCentralPubMedCrossRef

94.

Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209:51–60. doi:10.1084/jem.20111187.PubMedCentralPubMedCrossRef

95.

Bajenoff M, Egen JG, Koo LY, Laugier JP, Brau F, Glaichenhaus N, et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity. 2006;25:989–1001. doi:10.1016/j.immuni.2006.10.011.PubMedCentralPubMedCrossRef

Title: Extracellular Matrix Components in the Pathogenesis of Type 1 Diabetes
Authors: Marika Bogdani
Eva Korpos
Charmaine J. Simeonovic
Christopher R. Parish
Lydia Sorokin
Thomas N. Wight
Publication date: 01-12-2014
Publisher: Springer US
Published in: Current Diabetes Reports / Issue 12/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-014-0552-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2014

Stem Cell Therapy to Treat Heart Ischaemia: Implications for Diabetes Cardiovascular Complications

Glucokinase MODY and Implications for Treatment Goals of Common Forms of Diabetes

Bone as an Endocrine Organ Relevant to Diabetes

Interleukin 2 in the Pathogenesis and Therapy of Type 1 Diabetes

The Charcot Foot as a Complication of Diabetic Neuropathy

Type 2 Diabetes Pharmacoepidemiology Update 2014: Safety Versus Efficacy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage